I want to draw your attention to two posts on same subject and compare the tone .
So, a situation when the company got the rejection is being touted as a reason to rejoice. Yes - we heard that FDA did not raise questions on biosimilarity or efficacy of results et al. But FDA did ask more data and therefore cycle time goes up (at minimum).
The point I’m making is larger - I saw a similar commentary when the GMP concerns were raised by French authorities . Even the the company spun the story to be a positive one even though there was some 30 odd observations.
Is Biocon becoming one of those companies that is unable to be transparent with its investors?
Disc - I’m invested on the theme that everyone is but getting increasingly worried on reducing margin of safety (as BAU business seems to be going nowhere ) while upside seems elusive .